Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The...

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Statins are known to reduce coronary heart disease (CHD) events in individuals with risk factors.
• However, previous studies often lacked the power to assess all-cause mortality or subgroup outcomes.

Purpose of the Study:

• To evaluate the effect of pravastatin versus usual care on all-cause mortality in older, hypertensive, hypercholesterolemic individuals with additional CHD risk factors.

Main Methods:

• A randomized, nonblinded trial involving 10,355 participants aged 55+ with specific lipid profiles and hypertension.
• Participants were randomized to pravastatin (40 mg/d) or usual care, with follow-up for up to 8 years.

Main Results:

• All-cause mortality rates were similar between the pravastatin and usual care groups (14.9% vs. 15.3% at 6 years).
• Coronary heart disease (CHD) event rates also showed no significant difference (9.3% vs. 10.4% at 6 years).
• Pravastatin achieved a greater reduction in total cholesterol (17% vs. 8%) and LDL-C (28% vs. 11%) compared to usual care at 4 years.

Conclusions:

• Pravastatin did not significantly reduce all-cause mortality or CHD events compared to usual care in this population.
• The limited benefit may be attributed to a smaller difference in lipid-lowering effects between the groups compared to prior statin trials.